ANKRD26 Overexpression Triggers Megakaryocyte Apoptosis via JUNB-p21 Pathway

Deciphering the Myeloid Risk in Inherited Platelet Disorders

Inherited platelet disorders present a significant diagnostic challenge for clinicians, as these lifelong cytopenias are frequently misidentified as chronic immune thrombocytopenia [1, 2]. Among these conditions, ANKRD26-related thrombocytopenia 2 (THC2) is clinically critical due to its established association with a predisposition for myelodysplastic syndrome and acute myeloid leukemia [3, 4, 5]. Although the World Health Organization recognizes these germline predispositions in its classification of myeloid neoplasms, the mechanisms by which these mutations impair megakaryopoiesis, the process of platelet production from precursor cells, have remained largely theoretical [6, 7]. Current management typically relies on supportive care or thrombopoietin receptor agonists, which are agents that stimulate platelet production, yet the lack of targeted therapies reflects a gap in understanding how these genetic variants drive bone marrow failure [8, 9, 10]. A comprehensive study of four independent patients now provides a detailed molecular portrait of the cellular defects underlying this condition, identifying a consistent expansion of megakaryocyte progenitors and a marked reduction in polyploid megakaryocytes, which are mature cells containing multiple sets of chromosomes, driven by the JUNB-p21 signaling pathway [11].

Single-Cell Mapping of the Megakaryocyte Lineage

To overcome the inherent difficulties of studying rare and fragile bone marrow cells, the researchers employed single-cell transcriptomics, a technique that measures the gene activity of individual cells, alongside ex vivo functional profiling, which involves the analysis of living cells outside the body to observe their behavior. This crossvalidated analysis was conducted on bone marrow samples from 4 independent patients with THC2, providing a robust dataset to identify a conserved pathophysiologic phenotype. The scale of this investigation included the analysis of 47,281 THC2 CD34+ hematopoietic stem and progenitor cells (HSPCs), which are the early precursors capable of developing into all blood cell types, compared to 51,907 control HSPCs. By comparing these clinical samples against healthy subjects, the study established a high-resolution map of the hematopoietic landscape, allowing for a precise comparison of how the disease state alters early cell development.

Transcriptional Consequences of 5' UTR Variants

The molecular etiology of THC2 is rooted in germline variants located within the 5' untranslated region (UTR) of the ANKRD26 gene. The 5' UTR is a specific segment of messenger RNA that does not code for proteins itself but serves as a critical regulatory site for protein synthesis. In the index patient, the researchers identified a 5' UTR single-nucleotide variant, a mutation involving a single DNA base pair, that effectively removes the normal inhibitory controls on gene expression. This genetic alteration results in the persistent and significantly elevated expression of the ANKRD26 protein, a finding that contrasts with the typical silencing of this gene during the later stages of healthy platelet development. This pathological overexpression was documented across 4 megakaryocyte lineage subsets, including multipotent progenitors, common myeloid progenitors, megakaryocyte-erythroid progenitors, and megakaryocyte progenitors (MkP). Furthermore, this elevated ANKRD26 expression was also observed in terminally enriched primary megakaryocytes (pMKs), the most mature cells responsible for shedding platelets into the bloodstream. For the practicing clinician, these findings clarify the mechanism behind the maturation arrest observed in THC2 bone marrow, demonstrating that the defect is a systemic transcriptional dysregulation that begins at the progenitor level.

Centrosomal Localization and Mitotic Regulation

To determine how the overabundance of ANKRD26 protein physically disrupts platelet production, the researchers utilized confocal imaging, a high-resolution optical technique that uses spatial pinholes to eliminate out-of-focus light and pinpoint protein positions within cellular structures. Through this analysis, the study localized the ANKRD26 protein to the centrosome, which functions as the primary microtubule-organizing center of the cell. This finding is clinically significant because the centrosome is the structural hub responsible for orchestrating the assembly and orientation of the mitotic spindle, the machinery required for accurate chromosome segregation during cell division. By anchoring to this site, ANKRD26 is implicated in mitotic regulation during the maturation of megakaryocytes, suggesting that its presence at the centrosome is a key determinant of how these precursors navigate the transition from standard cell division to the specialized growth required for platelet release. The investigation also focused specifically on the later stages of development by analyzing 7,309 THC2 primary megakaryocytes (pMKs) and 5,077 control pMKs, revealing that while early progenitors were more numerous than in healthy controls, there was a simultaneous and marked reduction in polyploid megakaryocytes.

A Non-Canonical Pathway to Premature Cell Death

The study further elucidated the molecular machinery driving cellular loss, identifying that elevated ANKRD26 induces apoptosis in polyploid megakaryocytes via JUNB-mediated transcriptional activation of CDKN1A (p21). In this specific signaling cascade, the transcription factor JUNB triggers the expression of p21, a potent cyclin-dependent kinase inhibitor that halts the cell cycle and initiates programmed cell death. A critical distinction for clinicians is that this JUNB-p21 pathway operates independently of the canonical p53-PIDDosome axis, which is a protein complex typically involved in p53-mediated apoptosis following centrosomal or mitotic abnormalities. By bypassing this standard regulatory checkpoint, the ANKRD26-driven pathway represents a distinct form of marrow failure that does not rely on the typical p53 stress response. These findings provide a clear mechanistic target for future clinical intervention, as the researchers identified candidate therapeutic targets within the JUNB-p21 pathway to potentially restore platelet production. For the practicing physician, this suggests that modulating the activity of JUNB or the downstream expression of p21 could theoretically overcome the maturation block and allow these cells to reach the terminal stages of development required for effective thrombopoiesis in patients with THC2.

References

1. Dell’Orso G, Passarella T, Cappato S, et al. Chromosomal Deletion Involving ANKRD26 Leads to Expression of a Fusion Protein Responsible for ANKRD26-Related Thrombocytopenia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157330

2. Sánchez‐Fuentes A, Pérez-Botero J, Bastida JM, Rivera J. Diagnosis of Inherited Platelet Disorders: Clinical Evaluation and Functional and Molecular Assays. Biomolecules. 2025. doi:10.3390/biom15060846

3. Marconi C, Canobbio I, Bozzi V, et al. 5’UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. Journal of Hematology & Oncology. 2017. doi:10.1186/s13045-016-0382-y

4. Vyas H, Alcheikh A, Lowe G, Stevenson W, Morgan NV, Rabbolini DJ. Prevalence and natural history of variants in the ANKRD26 gene: a short review and update of reported cases. Platelets. 2022. doi:10.1080/09537104.2022.2071853

5. Arai H, Matsui H, Chi S, et al. Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25010652

6. Arber DA, Orazi A, Hasserjian RP, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016. doi:10.1182/blood-2016-03-643544

7. Xiao W, Nardi V, Stein EM, Hasserjian RP. A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC. Journal of Hematology & Oncology. 2024. doi:10.1186/s13045-024-01571-4

8. Chen X, Shukla M, Choi J. An unconquered challenge in MDS: review of pathophysiology, clinical manifestations, and management options of MDS with thrombocytopenia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06374-2

9. Urbański B, Bąbol-Pokora K, Braun M, et al. GFI1B mutations define an emerging form of inherited thrombocytopenia: insights from a case report and literature review. Annals of Hematology. 2026. doi:10.1007/s00277-026-06921-5

10. Bussel JB, Soff GA, Balduzzi A, Cooper N, Lawrence T, Semple JW. A Review of Romiplostim Mechanism of Action and Clinical Applicability. Drug Design Development and Therapy. 2021. doi:10.2147/dddt.s299591

11. Chen L, Hu L, Liu X, et al. Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21. Blood. 2026. doi:10.1182/blood.2025030017